Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Atrium Therapeutics (Nasdaq: RNA) announced it earned a $15 million development milestone from Bristol Myers Squibb (NYSE: BMY) after delivering a development candidate for a cardiology indication under their global collaboration.
Under the deal Atrium is eligible for up to $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits; Bristol Myers Squibb will fund future clinical development, regulatory, and commercialization activities.
Atrium Therapeutics (Nasdaq: RNA) awarded inducement equity grants on April 20, 2026 to seven newly hired non-executive employees under a new 2026 Inducement Plan adopted in April 2026.
The Awards total 101,250 stock options (exercise price $14.30) and 50,625 restricted stock units. Options and RSUs vest 25% after one year, then monthly or annual installments thereafter, subject to continued service. The Board's Human Capital Management Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (Nasdaq: RNA) launched on Feb 27, 2026 with approximately $270 million in cash to advance targeted RNA medicines for rare genetic cardiomyopathies. The company begins with two lead candidates: ATR 1072 (PRKAG2 syndrome) and ATR 1086 (PLN cardiomyopathy).
ATR 1072 is in IND-enabling studies with an IND targeted in H2 2026; ATR 1086 has CMC planned to support IND-enabling studies and is targeting an IND in 2027. Both programs could enter clinical trials pending supportive Phase 1 results.
Avidity Biosciences (Nasdaq: RNA) will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, March 8-11, 2026, in Orlando, Florida.
Presentations include 1-year Phase 1/2 EXPLORE44 del-zota data showing near normalization of creatine kinase and functional improvements in DMD44, multiple DM1 and FSHD studies, and the SAFARI44 Phase 3 design. Materials will be posted on the company publications page after the meeting.
Avidity Biosciences (NASDAQ: RNA) intends to adjourn its February 23, 2026 special meeting and reconvene on February 26, 2026 at 10:00 a.m. ET, to allow additional time to satisfy conditions for a pro rata distribution of SpinCo shares (Atrium Therapeutics) required for the Merger.
The Distribution is expected on February 26, 2026, the Merger closing is expected on February 27, 2026, and Avidity common stock will temporarily trade under RNAM on Nasdaq beginning the Distribution date. Record date remains January 29, 2026.
Avidity Biosciences (Nasdaq: RNA) announced Phase 1/2 MARINA results for delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) published in The New England Journal of Medicine on Feb 19, 2026. Treated participants showed an average ~40% reduction in DMPK mRNA and improvements in splicing, myotonia, muscle strength, mobility, and patient-reported function. Del-desiran had an acceptable safety profile overall; two serious adverse events occurred, one deemed drug-related and one led to discontinuation. The 4 mg/kg dose is in the global Phase 3 HARBOR study; topline 54-week readout expected in H2 2026.
Avidity Biosciences (Nasdaq: RNA) announced a record date of February 12, 2026 (close of business ET) for the pro rata distribution of Atrium Therapeutics common stock in a Spin-Off tied to the proposed Novartis acquisition.
Holders will receive one share of SpinCo per ten Avidity shares. Completion of the Merger and Spin-Off remains subject to closing conditions and Avidity stockholder approval; the Record Date may change based on the closing date.
Toll Brothers (NYSE:TOL) announced Enclave by Toll Brothers, a 35‑home luxury single‑family community coming to Corona, California, with site work underway at Santana Way and Garretson Ave and sales anticipated to begin in early fall 2026. Homes will feature one‑ and two‑story plans with up to 5 bedrooms, 4.5–5.5 baths, 2–4 car garages, and personalization via the Toll Brothers Design Studio. Community amenities include a park with green space, lounge seating and a BBQ area. The location offers access to hiking, shopping, dining and schools in the Corona‑Norco Unified School District. Contact (866) 232‑1631 or TollBrothers.com/CA for the interest list.
Avidity Biosciences (Nasdaq: RNA) announced a U.S. Managed Access Program (MAP) to provide investigational delpacibart zotadirsen (del-zota) to eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) under an FDA-authorized treatment protocol.
Enrollment is anticipated to begin by year-end 2025, and participants in EXPLORE44-OLE may transition to the MAP after completing two years of treatment. Avidity aligned with FDA after an October 2025 pre-BLA meeting and plans a BLA submission in 2026 seeking accelerated approval; patients would move to commercial supply if approved. Full MAP eligibility details will be posted on clinicaltrials.gov.
Avidity Biosciences (Nasdaq: RNA) announced a definitive merger agreement with Novartis valuing the company at about $12 billion, with closing expected in H1 2026 following the separation of early-stage cardiology programs into a new public SpinCo.
The company reported clear FDA alignment after an October 2025 pre-BLA meeting for del-zota, plans a 2026 BLA submission, and highlighted one-year data showing sustained muscle protection and reversal of disease progression. Del-zota holds Breakthrough Therapy designation.
Financials: cash and marketable securities of approximately $1.9 billion (9/30/25), expected to fund operations to mid-2028; Q3 collaboration revenue included a $10.0M milestone; Q3 R&D and G&A expenses rose materially versus 2024.